Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1963 2
1968 1
1969 2
1971 1
1983 1
1989 2
1990 1
1991 3
1992 5
1993 8
1994 2
1995 3
1996 5
1997 3
1998 2
1999 2
2000 1
2001 11
2002 2
2003 3
2004 9
2005 2
2006 3
2008 3
2009 5
2010 2
2011 4
2012 5
2013 9
2014 5
2015 8
2016 8
2017 12
2018 11
2019 13
2020 15
2021 12
2022 17
2023 15
2024 18

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

218 results

Results by year

Filters applied: . Clear all
Page 1
Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression.
Swindells S, Andrade-Villanueva JF, Richmond GJ, Rizzardini G, Baumgarten A, Masiá M, Latiff G, Pokrovsky V, Bredeek F, Smith G, Cahn P, Kim YS, Ford SL, Talarico CL, Patel P, Chounta V, Crauwels H, Parys W, Vanveggel S, Mrus J, Huang J, Harrington CM, Hudson KJ, Margolis DA, Smith KY, Williams PE, Spreen WR. Swindells S, et al. Among authors: pokrovsky v. N Engl J Med. 2020 Mar 19;382(12):1112-1123. doi: 10.1056/NEJMoa1904398. Epub 2020 Mar 4. N Engl J Med. 2020. PMID: 32130809 Clinical Trial.
Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection.
Orkin C, Arasteh K, Górgolas Hernández-Mora M, Pokrovsky V, Overton ET, Girard PM, Oka S, Walmsley S, Bettacchi C, Brinson C, Philibert P, Lombaard J, St Clair M, Crauwels H, Ford SL, Patel P, Chounta V, D'Amico R, Vanveggel S, Dorey D, Cutrell A, Griffith S, Margolis DA, Williams PE, Parys W, Smith KY, Spreen WR. Orkin C, et al. Among authors: pokrovsky v. N Engl J Med. 2020 Mar 19;382(12):1124-1135. doi: 10.1056/NEJMoa1909512. Epub 2020 Mar 4. N Engl J Med. 2020. PMID: 32130806 Clinical Trial.
Long-Acting Injectable Cabotegravir + Rilpivirine for HIV Maintenance Therapy: Week 48 Pooled Analysis of Phase 3 ATLAS and FLAIR Trials.
Rizzardini G, Overton ET, Orkin C, Swindells S, Arasteh K, Górgolas Hernández-Mora M, Pokrovsky V, Girard PM, Oka S, Andrade-Villanueva JF, Richmond GJ, Baumgarten A, Masiá M, Latiff G, Griffith S, Harrington CM, Hudson KJ, St Clair M, Talarico CL, Patel P, Cutrell A, Van Eygen V, D'Amico R, Mrus JM, Wu S, Ford SL, Chow K, Roberts J, Wills A, Walters N, Vanveggel S, Van Solingen-Ristea R, Crauwels H, Smith KY, Spreen WR, Margolis DA. Rizzardini G, et al. Among authors: pokrovsky v. J Acquir Immune Defic Syndr. 2020 Dec 1;85(4):498-506. doi: 10.1097/QAI.0000000000002466. J Acquir Immune Defic Syndr. 2020. PMID: 33136751 Free PMC article. Clinical Trial.
Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials.
Cahn P, Madero JS, Arribas JR, Antinori A, Ortiz R, Clarke AE, Hung CC, Rockstroh JK, Girard PM, Sievers J, Man C, Currie A, Underwood M, Tenorio AR, Pappa K, Wynne B, Fettiplace A, Gartland M, Aboud M, Smith K; GEMINI Study Team. Cahn P, et al. Lancet. 2019 Jan 12;393(10167):143-155. doi: 10.1016/S0140-6736(18)32462-0. Epub 2018 Nov 9. Lancet. 2019. PMID: 30420123 Clinical Trial.
Sphingolipid Metabolism in Tumor Cells.
Pokrovsky VS, Ivanova-Radkevich VI, Kuznetsova OM. Pokrovsky VS, et al. Biochemistry (Mosc). 2023 Jul;88(7):847-866. doi: 10.1134/S0006297923070015. Biochemistry (Mosc). 2023. PMID: 37751859 Free article. Review.
Safety and efficacy of doravirine as first-line therapy in adults with HIV-1: week 192 results from the open-label extensions of the DRIVE-FORWARD and DRIVE-AHEAD phase 3 trials.
Orkin C, Molina JM, Cahn P, Lombaard J, Supparatpinyo K, Kumar S, Campbell H, Wan H, Teal V, Jin Xu Z, Asante-Appiah E, Sklar P, Teppler H, Lahoulou R; DRIVE-FORWARD and DRIVE-AHEAD collaborators. Orkin C, et al. Lancet HIV. 2024 Feb;11(2):e75-e85. doi: 10.1016/S2352-3018(23)00258-8. Epub 2023 Dec 20. Lancet HIV. 2024. PMID: 38141637 Clinical Trial.
L-Lysine α-Oxidase: Enzyme with Anticancer Properties.
Lukasheva EV, Babayeva G, Karshieva SS, Zhdanov DD, Pokrovsky VS. Lukasheva EV, et al. Among authors: pokrovsky vs. Pharmaceuticals (Basel). 2021 Oct 22;14(11):1070. doi: 10.3390/ph14111070. Pharmaceuticals (Basel). 2021. PMID: 34832852 Free PMC article. Review.
Pescia and Pokrovsky reply.
Pescia D, Pokrovsky V V. Pescia D, et al. Among authors: pokrovsky v v. Phys Rev Lett. 1993 Feb 22;70(8):1185. doi: 10.1103/PhysRevLett.70.1185. Phys Rev Lett. 1993. PMID: 10054311 No abstract available.
Smart nanocarriers for enzyme-activated prodrug therapy.
Abo Qoura L, Morozova E, Ramaa СS, Pokrovsky VS. Abo Qoura L, et al. Among authors: pokrovsky vs. J Drug Target. 2024 Nov;32(9):1029-1051. doi: 10.1080/1061186X.2024.2383688. Epub 2024 Jul 26. J Drug Target. 2024. PMID: 39045650 Review.
[Chronic hepatitis C in Russia: current challenges and prospects].
Chulanov VP, Pimenov NN, Mamonova NA, Sagalova OI, Shestakova IV, Pokrovsky VI. Chulanov VP, et al. Among authors: pokrovsky vi. Ter Arkh. 2015;87(11):5-10. doi: 10.17116/terarkh201587115-10. Ter Arkh. 2015. PMID: 26821409 Review. Russian.
218 results